FUTRUE is an international healthcare group headquartered in Gräfelfing, Germany, with operations spanning multiple countries. Founded in 2008, the company comprises over 20 subsidiary companies, each operating with lean, highly specialized, and independent teams typically numbering fewer than 180 employees. Its focus areas include biopharmaceuticals, probiotics, neuroscience, medical technology, brain-computer interface technology, clinical research, and pharmaceutical media.
The group's research and development activities have resulted in more than 90 drug approvals to date. Among its product portfolio is VER-01, a cannabinoid-based pain medication developed as an alternative to opioid treatments, and Kijimea, a probiotic brand commercialized through its subsidiary SYNformulas.
FUTRUE operates across multiple industry verticals within healthcare and pharmaceuticals, developing what it describes as transformative medicines and technologies. The organization coordinates its subsidiaries under the guiding concept of rethinking health.
